Life Sciences Executive Joins Patheon
This article was originally published in Scrip
Patheon has appointed Gilles Cottier president of the company's pharmaceutical development services (PDS) division and he will serve as a member of the company's executive committee – effective immediately. In his previous 25 years at Sigma-Aldrich, Cottier held various positions of increasing responsibility.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.